Abstract | BACKGROUND: METHODS: RESULTS: The activity and toxicity of docetaxel were assessed in all 38 patients who were entered on the study. No Grade 3-4 toxicities were recorded. No treatment delays were required because of toxicity or dose reductions. Responses were observed in 42% of patients (95% confidence interval, 26-58%). The median duration of response was 8.39 months, the estimated median overall survival was 11.3 months, and the 1-year survival rate was 39%. CONCLUSIONS:
|
Authors | Ricardo Hitt, Maria L Amador, Miguel Quintela-Fandino, Antonio Jimeno, Olga del Val, Susana Hernando, Hernan Cortes-Funes |
Journal | Cancer
(Cancer)
Vol. 106
Issue 1
Pg. 106-11
(Jan 01 2006)
ISSN: 0008-543X [Print] United States |
PMID | 16329139
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | Copyright 2005 American Cancer Society. |
Chemical References |
- Antineoplastic Agents, Phytogenic
- Taxoids
- Docetaxel
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy, mortality, secondary)
- Docetaxel
- Drug Administration Schedule
- Female
- Head and Neck Neoplasms
(drug therapy, mortality, pathology)
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, mortality)
- Survival Rate
- Taxoids
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|